Unknown PHASE4 INTERVENTIONAL 2-arm NCT01610141

Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients

Sponsor: Chinese PLA General Hospital

Conditions Atrial Fibrillation Deep Vein Thrombosis Heart Valve Disease Pulmonary Embolism

Interventions Genotype-guided warfarin dosing Non-genotype guided warfarin dosing

Updated 6 times since 2017 Last updated: Oct 7, 2013 Started: Jun 30, 2012 Primary completion: Jun 30, 2014 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01610141, this PHASE4 trial focuses on Atrial Fibrillation and Deep Vein Thrombosis and remains ongoing. Sponsored by Chinese PLA General Hospital, it has been updated 6 times since 2012, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE4

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese PLA General Hospital

Data source: Chinese PLA General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China